Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.32 |
| ▸ | S100A9 | P06702 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900559 | 0.81 | MAPK14 (0.32) | — | |
| SCHEMBL21847399 | 0.75 | APP (0.39) | DHODHS1PR3S1PR1IRAK4MEN1 | |
| SCHEMBL2698210 | 0.75 | DHODH (0.36) | DHODHPOLBS1PR3S1PR1S100A9 | |
| SCHEMBL195153 | 0.74 | SMN1; SMN2 (0.40) | POLBMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL28482242 | 0.73 | APP (0.38) | DHODHS1PR3S1PR1IRAK4MEN1 | |
| SCHEMBL16302880 | 0.73 | AHR (0.48) | POLBGAAMEN1KMT2A | |
| SCHEMBL30127342 | 0.71 | PTK2 (0.49) | DHODHIRAK4MEN1HTTKMT2A | |
| SCHEMBL12515442 | 0.71 | PTK2 (0.49) | DHODHIRAK4MEN1HTTKMT2A | |
| SCHEMBL7691715 | 0.71 | MAPT (0.32) | DHODHPOLBS1PR3S1PR1GAA | |
| SCHEMBL17131647 | 0.70 | IRAK4 (0.43) | DHODHS1PR3S1PR1IRAK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12275741-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-118955409-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-112867539-B | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3843842-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-112867539-A | Cardiac muscle segment inhibitor | 赛特凯恩蒂克公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
| US-12275741-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | DHODH 3164/4885POLB 2305/4885S1PR3 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.